Ea6174- A Phase III Randomized Trial Of Comparing Adjuvant Mk-3475 (Pembrolizumab) To Standard Of Care Observation In Completely Resected Merkel Cell Carcinoma
Posted Date: Aug 8, 2019
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology, Skin Cancer
- Type of Study: Drug
The goal of this study is to compare Overall Survival (OS) and Recurrence Free Survival (RFS) as co-primary endpoints across the two arms.
To Be Eligible: 18 Years Or Older, Nonpregnant/Breastfeeding, Diagnosed With Merkel Cell Carcinoma, Must Not Have Recent Life Threatening Illness Or Cancer Within 2 Years.
Skin Cancer, Merkel Cell
For More Information:
Uc Cancer Institute